Benoit Follin-Arbelet

Benoit Follin-Arbelet

Auto-generated profile, based on publicly available information

Benoit Follin-Arbelet

Department of Molecular Pathology Akershus University Hospital Lørenskog Norway

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
BFBenoit Follin-Arbelet
Benoit Follin-Arbelet
MSMilada Cvancarova Småstuen
Milada Cvancarova Småstuen
ØHØistein Hovde
Øistein Hovde
LJLars-Petter Jelsness-Jørgensen
Lars-Petter Jelsness-Jørgensen
BMBjørn Moum
Bjørn Moum
Background and Aims: Patients with longstanding inflammatory bowel disease [IBD] may be at an increased risk of death compared to the general population, especially elderly patients. The Inflammatory Bowel South-Eastern Norway [IBSEN] study has previously detected a small but not statistically significant increase in mortality 20 years after diagnosis. The aim of this study was to evaluate the overall and cause-specific mortality at 30 years of follow-up. Methods: The IBSEN cohort included 519 incident patients with ulcerative colitis [UC] and 237 patients with Crohn’s disease [CD] between 1990 and 1993, each matched with five controls. Death certificate data were obtained from the Norwegian Cause of Death Registry. The underlying causes of death were categorized into five groups: all cancers, gastrointestinal cancers, cardiovascular diseases, infections and all other causes. Hazard ratios [HRs] were modelled using Cox regression. Results: There was no statistically significant difference in the overall mortality rates. However, in patients with CD, male sex (HR = 1.65 [95% CI: 1.04–2.62]), onset after 40 years of age (HR = 1.72 [1.19–2.48]), colonic disease (HR = 1.57 [1.05–2.35]) and penetrating behaviour (HR = 3.3 [1.41–7.76]) were clinical factors associated with an increased mortality. IBD patients were at a higher risk of death due to cardiovascular disease: HR = 1.51 [1.10–2.08] for UC and 2.04 [1.11–3.77] for CD. When taking into account both the underlying and the immediate cause of death, infection was more frequent in patients with IBD. Conclusions: Overall, all-cause mortality rates were similar between patients with IBD and controls. However, clinicians should remain alert to cardiovascular diseases and infections, particularly in specific subgroups of CD patients.

1 October 2023 in Crohn's & Colitis 360
Verified
Journal Article
Open access
PDF file
BFBenoit Follin-Arbelet
Benoit Follin-Arbelet
MSMilada Cvancarova Småstuen
Milada Cvancarova Småstuen
ØHØistein Hovde
Øistein Hovde
LJLars-Petter Jelsness-Jørgensen
Lars-Petter Jelsness-Jørgensen
BMBjørn Moum
Bjørn Moum
Background: Patients with Crohn’s disease (CD) are most often diagnosed as young adults; therefore, long-term studies are needed to assess the risk of cancer over their lifetime. Thus, the aims of the present study were to determine the risk of cancer in a Norwegian population-based cohort (the Inflammatory Bowel South Eastern Norway [IBSEN] study), 30 years after diagnosis, and to assess whether patients with CD were at an increased risk of specific cancer types. Methods: The IBSEN cohort prospectively included all incident patients diagnosed between 1990 and 1993. Data on cancer incidence were obtained from the Cancer Registry of Norway. Overall and cancer-specific hazard ratios (HRs) for CD patients compared with age- and sex-matched controls were modeled using Cox regression. Standardized incidence ratios (SIRs) were estimated compared to the general population. Results: In total, the cohort included 237 patients with CD, and 36 of them were diagnosed with cancer. Compared to the general Norwegian population, patients with CD had an increased overall risk of cancer (HR = 1.56, 95% CI: 1.06–2.28), particularly male patients (HR = 1.85, 95% CI: 1.08–3.16). The incidence of lung cancer and nonmelanoma skin cancer was increased; however, the difference was not statistically significant (SIR = 2.29, 95% CI: 0.92–4.27 and SIR = 2.45, 95% CI: 0.67–5.37, respectively). Conclusions: After 30 years of follow-up, the risk of all cancers in patients with CD was increased compared to the general population.

25 August 2015 in APMIS
Verified
Journal Article
Closed access
PDF file
HTHege Tunsjø
Hege Tunsjø
AKAnne K. Kvissel
Anne K. Kvissel
BFBenoit Follin-Arbelet
Benoit Follin-Arbelet
BBBeth-Marie Brotnov
Beth-Marie Brotnov
TRTrond E. Ranheim
Trond E. Ranheim
TLTruls M. Leegaard
Truls M. Leegaard

20 June 2023 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Open access
BFBenoit Follin-Arbelet
Benoit Follin-Arbelet
MSMilada Cvancarova Småstuen
Milada Cvancarova Småstuen
ØHØistein Hovde
Øistein Hovde
LJLars-Petter Jelsness-Jørgensen
Lars-Petter Jelsness-Jørgensen
BMBjørn Allan Moum
Bjørn Allan Moum
ObjectivesPatients with ulcerative colitis (UC) have shown an increased risk for colorectal cancer, hepatobiliary, hematologic, and skin cancers, but updated long-term data is needed. This study aimed to estimate the risk of cancer in patients with UC compared to the general Norwegian population, in a population-based cohort (the IBSEN study), 30 years after diagnosis; and to identify possible risk factors associated with cancer.MethodsThe IBSEN cohort prospectively included all incident patients between 1990 and 1993. Cancer incidence data were obtained from the Cancer Registry of Norway. The overall and cancer-specific hazard ratios (HR) were modelled using Cox regression. Standardized incidence ratios were estimated compared to the general population.ResultsIn total, the cohort included 519 patients, and 83 cases were diagnosed with cancer. There was no statistically significant difference in the overall cancer risk (HR = 1.01, 95% CI: [0.79-1.29]) and colorectal cancer risk (HR = 1.37, 95% CI: [0.75-2.47]) between patients and controls. The incidence of biliary tract cancer was higher than expected (SIR = 9.84, 95%CI: [3.19-20.15]), especially when UC patients suffered from primary sclerosing cholangitis. Male UC patients were also more at risk of being diagnosed with hematologic malignancies (HR = 3.48, 95% CI: [1.55-7.82]). Being prescribed thiopurines was associated with a higher risk of cancer (HR = 2.03, 95% CI: [1.02-4.01]).ConclusionsAt 30 years after diagnosis, the risk of all cancer in patients with UC was not significantly increased compared with the general population. However, the risks of biliary tract cancer and hematologic cancers were increased, particularly in male patients.

15 January 2026 in JCC Plus
Verified
Journal Article
Open access
BFBenoit Follin‐Arbelet
Benoit Follin‐Arbelet
KMKristian Marling Moum
Kristian Marling Moum
BMBjørn Allan Moum
Bjørn Allan Moum
Aim: The COVID‐19 pandemic caused substantial changes in the routine management of patients with inflammatory bowel disease (IBD). The aim of this study was to survey the experience and the concerns of patients at the IBD outpatient clinic two years after the beginning of the pandemic. Subjects and Methods: Patients (≥ 18 years old) from the Oslo University Hospital IBD outpatient clinic were recruited during follow‐up visits. A written self‐report questionnaire covering various aspects on COVID‐19 and medical care was answered. Results: A total of 609 IBD patients were included. 387 (63%) patients reported a history of COVID‐19 and the vaccination rate was 98%. Patients reported feeling safe when visiting the outpatient clinic (97%) and were satisfied with the information they received (92%). One‐fifth of patients believed that IBD increased the risk of COVID‐19, whereas 43% believed that medical treatment for IBD increased the risk of COVID‐19, a higher percentage compared to 2020. One in five patients had cancelled scheduled hospital visits due to COVID‐19 and 10% had preferred phone consultation. Only 21 (3.7%) patients self‐discontinued their medical treatment, indicating good adherence to both treatment and follow‐up. Conclusion: Most patients were satisfied with the healthcare services and the information provided at the outpatient clinic, although concerns about COVID‐19 and IBD treatment persisted. There was good adherence to physical follow‐up and treatment.